The need for new antimalarial drugs less prone to resistance

Current Pharmaceutical Design

Volumn 19, Issue 2, 2013, Pages 266-269

  Noedl, Harald ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Artemisinin resistance; Artemisinin based combination therapy; Combination therapy; Plasmodium falciparum malaria; Therapy

Indexed keywords

ALBITIAZOLIUM BROMIDE; ANTIMALARIAL AGENT; ARTEMISININ; ARTEROLANE; CHLOROQUINE; FERROQUINE; FOSMIDOMYCIN; MALARIA VACCINE; MEFLOQUINE; NITD 609; PIPERAQUINE; UNCLASSIFIED DRUG;

ANTIMALARIAL DRUG RESISTANCE; ARTICLE; DISEASE TRANSMISSION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG SAFETY; DRUG TARGETING; ENDEMIC DISEASE; HUMAN; MALARIA; MALARIA CONTROL; MALARIA FALCIPARUM; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; TREATMENT DURATION;

EID: 84877931042     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161213804070302     Document Type: Article

References (29)

1. World Health Organization. World Malaria Report 2010. Geneva; WHO Press 2011.
2. CRIMALDDI-The Coordination, Rationalisation and Integration of Antimalarial Drug Discovery and Development Initiatives. Malaria: A roadmap for drug discovery. http://www.crimalddi.eu/docs/ documents/BusinessPlanv13.pdf last accessed May 2012.
3. Bell A, Boehm D. Anti-disease therapy for malaria-'resistance proof'? Curr Pharm Des 2012; in press.
4. Nocht B, Werner H. Beobachtungen ueber eine relative Chininresistenz bei Malaria aus Brasilien. Dtsch Med Wschr 1910; 36: 1557-60.
5. Neiva A. Ueber die Bildung einer chininresistenten Rasse des Malariaparasiten. Mem Inst Oswaldo Cruz 1910; 2: 131-40.
6. Wongsrichanalai C, Pickard AL, Wernsdorfer WH, Meshnick SR. Epidemiology of drug-resistant malaria. Lancet Infect Dis 2002; 2(4): 209-18.
7. Miller LH, Su X. Artemisinin: discovery from the Chinese herbal garden. Cell 2011; 146(6): 855-8.
8. Chen PQ, Li GQ, Guo XB, et al. The infectivity of gametocytes of Plasmodium falciparum from patients treated with artemisinin. Chin Med J 1994; 107: 709-11.
9. World Health Organitation. Guidelines for the treatment of malaria, second edition. Geneva; WHO Press 2010.
10. Dondorp A, Nosten F, Stepniewska K, Day N, White N. South East Asian Quinine Artesunate Malaria Trial (SEAQUAMAT) group. Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial. Lancet 2005; 366(9487): 717-25.
11. Dondorp AM, Fanello CI, Hendriksen IC, et al. Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial. Lancet 2010; 376(9753): 1647-57.
12. World Health Organization. Antimalarial drug combination therapy: Report of a WHO technical consultation, 4-5 April 2001. Geneva, (WHO/CDS/RBM/2001.35).
13. White NJ. Preventing antimalarial drug resistance through combinations. Drug Resist Updat 1998; 1: 3-9.
14. Giao PT, de Vries PJ. Pharmacokinetic interactions of antimalarial agents. Clin Pharmacokinetics 2001; 40: 343-373.
15. Noedl H. Combination Therapy in Light of Emerging Artemisinin Resistance. In: Staines HM, Krishna S. Eds. Treatment and Prevention of Malaria. Milestones in Drug Therapy pp. 213-225. Basel; Springer 2011.
16. Noedl H, Se Y, Schaecher K, Smith BL, Socheat D, Fukuda MM. Artemisinin Resistance in Cambodia 1 (ARC1) Study Consortium. Evidence of artemisinin-resistant malaria in western Cambodia. N Engl J Med 2008; 359: 2619-2620
17. Noedl H, Socheat D, Satimai W. Artemisinin-resistant malaria in Asia. N Engl J Med 2009; 361: 540-541
18. Dondorp AM, Nosten F, Yi P, et al. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 2009; 361: 455-467
19. World Health Organization. WHO briefing on malaria treatment guidelines and artemisinin monotherapies. WHO Press, 2006.
20. Thanh NV, Toan TQ, Cowman AF, et al. Monitoring for Plasmodium falciparum drug resistance to artemisinin and artesunate in Binh Phuoc Province, Vietnam: 1998-2009. Malar J 2010; 9: 181
21. Thang NDEA, le Hung X, le Thuan K, et al. Rapid decrease of malaria morbidity following the introduction of community-based monitoring in a rural area of central Vietnam. Malar J 2009; 8: 3
22. Färnert A, Lindberg J, Gil P, et al. Evidence of Plasmodium falciparum malaria resistant to atovaquone and proguanil hydrochloride: case reports. BMJ 2003; 326(7390): 628-9.
23. Prudêncio M, Mota MM. Targeting host factors to circumvent antimalarial drug resistance. Curr Pharm Des 2012; in press.
24. Medicines for Malaria Venture. MMV's portfolio at end of 1st quarter, 2012. http://www.mmv.org/sites/default/files/uploads/docs/RandD/1Q_M MV_Portfolio_Slide.ppt last accessed May 2012.
25. Gamo FJ, Sanz LM, Vidal J, et al. Thousands of chemical starting points for antimalarial lead identification. Nature. 2010; 465(7296): 305-10.
26. Garcia-Bustos JF, Gamo FJ. Antimalarial Drug Resistance and Early Drug Discovery. Curr Pharm Des 2012; in press.
27. Charman SA, Arbe-Barnes S, Bathurst IC, et al. Proc Natl Acad Sci USA 2011; 108(11): 4400-5.
28. Rottmann M, McNamara C, Yeung BK, et al. Spiroindolones, a potent compound class for the treatment of malaria. Science 2010; 329(5996): 1175-80.
29. Greenwood BM, Targett GAT. Malaria vaccines and the new malaria agenda. Clin Microbiol Infect 2011; 17: 1600-7.